Procter & Gamble (PGHL) | Stock Overview & Key Data
Procter & Gamble Performance Comparison
Stock Range
Today's Range
Low: ₹6,182.50
High: ₹6,374.00
on August 14, 2025
52 Week Range
Low: ₹4,863.00
High: ₹6,500.00
on October 29, 2024
on August 1, 2025
All-Time High: ₹7,500.00 on February 8, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR105.3B
EPS
111.00
P/E Ratio (TTM)
57.14
Forward P/E
N/A
P/B Ratio
19.56
PEG Ratio
-4.58
Div. Yield
2.35%
ROE
37.41%
Beta
0.429
Debt to Equity
0.01
Financial Highlights
Profitability
Gross Margin
72.25%
Operating Margin
25.06%
Profit Margin
20.62%
Returns and Earnings
Return on Assets (TTM)
25.30%
Return on Equity (TTM)
37.41%
EBITDA
INR4.2B
Net Income (TTM)
INR2.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR733.79
Quarterly Revenue Growth (YoY)
19.30%
Quarterly Earnings Growth (YoY)
294.40%
Dividend Information
Last 12-Month Dividend
₹140.00
Current Dividend Yield
2.35%
3-Year Average Dividend Yield
0.99%
3-Year Average Annual Dividend
₹98.83
3-Year Total Dividends
₹296.50
Ex-Dividend Date
February 21, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Procter & Gamble PGHL | 105.29B Mid-cap | -0.29% | 8.24% | 20.33% | 20.19% | 20.61% | 21.68% | 43.85% | 33.86% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 2.69% | -2.45% | -3.91% | -3.48% | -13.15% | -5.82% | 82.10% | 208.33% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | 0.02% | -9.53% | -1.34% | 4.94% | 0.98% | 32.34% | 65.91% | 88.85% |
| Alembic APLLTD | 188.36B Mid-cap | 0.69% | -7.13% | 5.43% | 16.97% | -8.78% | -12.16% | 46.82% | -4.25% |
| Jubilant Pharmova JUBLPHARMA | 167.27B Mid-cap | -4.29% | -11.56% | 16.76% | 11.75% | -2.21% | 23.67% | 205.56% | 69.94% |
| Neuland Laboratories NEULANDLAB | 170.36B Mid-cap | 3.48% | -8.73% | 6.45% | 12.29% | -7.11% | 13.83% | 1,082.21% | 1,292.04% |
Ownership & Short Interest
Insider Ownership
52.19%
Institutional Ownership
16.31%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
43K
Average 90-Day Volume
23K
Procter & Gamble Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Procter & Gamble would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PGHL's 52-week high and low?
- In the last 52 weeks, Procter & Gamble reached a high of ₹6,500.00 (on August 1, 2025) and a low of ₹4,863.00 (on October 29, 2024).
- What is the market cap and P/E ratio for PGHL?
- Curious about Procter & Gamble's size and valuation? Its market capitalization stands at 105.29B. When it comes to valuation, the P/E ratio (trailing twelve months) is 57.14, and the forward P/E (looking ahead) is N/A.
- Does PGHL pay dividends? If so, what's the yield?
- Yes, Procter & Gamble is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.35%, and the company has paid an average of ₹98.83 per share annually over the past 3 years.
- Who are Procter & Gamble's main competitors or similar companies to consider before investing?
When looking at Procter & Gamble, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -5.82% 82.10% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 32.34% 65.91% Alembic
APLLTD188.36B Healthcare Drug Manufacturers - Specialty & Generic -12.16% 46.82% Jubilant Pharmova
JUBLPHARMA167.27B Healthcare Drug Manufacturers - Specialty & Generic 23.67% 205.56% Neuland Laboratories
NEULANDLAB170.36B Healthcare Drug Manufacturers - Specialty & Generic 13.83% 1,082.21% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Procter & Gamble Health Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Procter & Gamble's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 37.41%, the Debt to Equity ratio from the most recent quarter is 0.01, and its Gross Profit Margin stands at 72.25%.
- What is the recent revenue and earnings growth for PGHL?
- Looking at Procter & Gamble's growth, its revenue over the trailing twelve months (TTM) was INR12B. Compared to the same quarter last year (YoY), quarterly revenue grew by 19.30%, and quarterly earnings saw a YoY growth of 294.40%.
- How much of PGHL stock is held by insiders and institutions?
- Wondering who owns Procter & Gamble stock? Company insiders (like executives and directors) hold about 52.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 16.31%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.